Israeli drug companies, such as Teva, are pretty good at producing imitation drugs quickly. Teva was truly disruptive to big pharma companies, since they often feared blockbuster drugs going off patent as Teva was ready and waiting with a quality generic imitation. It’s not so surprising that what is bad for big pharma is good for the patient and the consumer, and now an Israeli biotech company named Protalix is ready to replenish supplies of the experimental Ebola vaccine, ZMapp.
The disease has already claimed the lives of 3, 944, predominantly in Africa, but in the U.S., there has been one casualty and another one infected. The World Health Organization hoped to have a vaccine by November, but even if ZMapp can be available by the target date, supplies will be insufficient to meet requirements. However, the Times of Israel reports that Protalix can step in and produce as much ZMapp as is needed. In an interview with Channel 2, executive vice president of research and development at Protalix, Yossie Shaaltiel, said, “Today, our production capacity exceeds our needs, and we would certainly be happy to have our company produce the Ebola drug for them. We know how to do it effectively, in large quantities and in a relatively short period of time.”
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
I have a feeling BDS is going to be strangely silent about this outrage.
